We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
- Authors
Yeo, Winnie; Chung, Hyun C; Chan, Stephen L; Wang, Ling Z; Lim, Robert; Picus, Joel; Boyer, Michael; Mo, Frankie K F; Koh, Jane; Rha, Sun Y; Hui, Edwin P; Jeung, Hei C; Roh, Jae K; Yu, Simon C H; To, Ka F; Tao, Qian; Ma, Brigette B; Chan, Anthony W H; Tong, Joanna H M; Erlichman, Charles; Chan, Anthony T C; Goh, Boon C
- Abstract
Epigenetic aberrations have been reported in hepatocellular carcinoma (HCC). In this study of patients with unresectable HCC and chronic liver disease, epigenetic therapy with the histone deacetylase inhibitor belinostat was assessed. The objectives were to determine dose-limiting toxicity and maximum-tolerated dose (MTD), to assess pharmacokinetics in phase I, and to assess activity of and explore potential biomarkers for response in phase II.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 27, p3361
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.41.2395